Scientists identify chimeric RNA molecules as essential in cellular health and disease, finding they play a wide variety of critical roles in vital cellular processes. Faulty chimeric RNA are often malfunctioning in breast cancer tumors, prompting new cancer treatments targeting specific chimeras.
Pregabalin misuse rates in Australia have declined by 25% and 47% following media coverage and prescribing restrictions, with dispenses decreasing significantly in December 2018, May 2020, and December 2021. Despite ongoing concerns, the decline suggests similar interventions in other countries may be effective in reducing misuse.
Researchers have identified complement factor B as a promising target for pancreatic cancer treatment. Inhibiting this enzyme suppresses cancer growth, induces cellular senescence, and remodels the tumor immune microenvironment. The combination of CFB inhibition with chemotherapy and immunotherapy showed the greatest tumor suppression.
Patients with excessive polypharmacy (10+ medications) and complex medication regimens experience significantly greater physician burden. Multidisciplinary collaboration between physicians and pharmacists can optimize pharmacotherapy and reduce physician burden.
A study of 1,088 adults aged 18 to 55 found that those who used classic psychedelics, such as psilocybin and LSD, in their younger years reported lower anxiety and depression scores than non-users, but this association weakened with age. The research, published in Scientific Reports, highlights the importance of age as a moderating fac...
Phase 3 clinical trials involving over 1,000 participants found that those taking retatrutide, a new experimental weight-loss injectable drug, lost about a quarter of their body weight on average and experienced significant pain relief. The drug also showed benefits in reducing blood pressure, lipid levels, and systemic inflammation.
Researchers review evidence on obesity drugs, finding potential benefits for brain function, especially for those with type 2 diabetes or obesity. They call for clinical trials to track cognitive abilities and emphasize the importance of monitoring older patients.
The UVA Biotech Innovation Fund will support the SPARK Innovative Medicines program, helping to accelerate promising discoveries into new treatments and cures. The fund will provide long-term support for researchers to overcome the critical gap between discovery and clinical application.
China's contributions to treating chronic hepatitis B focus on identifying patients most likely to benefit from shorter courses of therapy. Emerging treatments like bepirovirsen show promise, but durability and effectiveness remain uncertain.
Researchers hope to enroll over 2,000 stroke patients to test cilostazol's effectiveness in reducing stroke recurrence. The study aims to cut stroke recurrence by 50% and follows Japan's success with similar results.
A multinational study of over 460,000 people finds that ADHD medication use is not associated with an increased risk of self-harm. The study suggests that individuals with ADHD are already at their highest risk of self-harm before treatment begins, highlighting the importance of early intervention.
Researchers propose using aging rate indicators to detect interventions that slow aging pace. The study aims to accelerate anti-aging breakthroughs, but regulatory barriers and equitable access are discussed.
A new AI platform, MAESTRO, has been developed to identify promising drug combinations for overcoming treatment resistance in prostate cancer. The platform uses large language models to analyze scientific knowledge and ranks the most promising candidates, providing a clear biological rationale for experimental testing.
Researchers systematically summarize how epigenetic modifications and metabolic reprogramming interact to drive hepatocellular carcinoma. The review highlights the epigenetic-metabolism axis as a promising therapeutic target and offers new insights for treatment.
A new UVA study finds that Black children are more likely to develop severe asthma due to harmful inflammation, regardless of environmental factors. The research suggests tailored treatments for Black children with severe symptoms, and testing for high levels of T2 inflammation in all children with difficult-to-treat asthma.
Researchers used AI to analyze nearly 150,000 Reddit posts about unapproved GLP-1 weight loss drug retatrutide, identifying potential side effects that differ from clinical trial results. The study found increased appetite to be the most frequently reported symptom, which contrasts with gastrointestinal complaints identified in Phase 2...
A nationwide Finnish registry study investigated medication-related osteonecrosis of the jaw in breast cancer patients receiving antiresorptive treatment. The study found that 12.6% of patients developed the condition, with associations between dental procedures and its risk. The findings emphasize the need for close collaboration betw...
Juvmo, a Parkinson's disease drug, has been approved by the FDA and offers a new treatment option for patients, potentially reducing side effects. The drug's unique mechanism of action provides relief from motor symptoms, and its approval marks a significant milestone in the research of UVA Health scientists.
A pilot study found that low-dose LSD improves women's sustained attention, but has no effect on men's attention. The study, led by Iva Totomanova, involved 24 women and 24 men, and used a double-blind placebo-controlled design. The results suggest that people may respond differently to LSD depending on their sex, cognitive task, and c...
Researchers captured rapid chemical stages in penicillin formation, revealing the role of water molecules and enzyme movements in guiding the reaction. The study provides unprecedented insights into the mechanism of β-lactam antibiotic biosynthesis, shedding light on the complex chemistry involved in creating this crucial medicine.
A Cochrane review found that marketing strategies, including payments and gifts, can influence physicians' prescribing habits, leading to more expensive and less appropriate drug prescriptions. The review suggests that robust conflict-of-interest policies can mitigate these influences.
Researchers found that well-designed digital alerts can assist clinicians in high-pressure situations, prompting them to make recommended treatment decisions and recognize when patients are deteriorating. The studies demonstrated the effectiveness of electronic health record alerts in the emergency department and cardiac intensive care...
A recent study has raised concerns about the safety of antifungal treatments during pregnancy, finding potential changes in fetal hormone production and its effects on children. Researchers analyzed data from 589 Danish mother-child pairs and found altered adrenal hormone levels in children after birth.
A global survey of over 1,100 patients, caregivers, and healthcare providers found that 69% noticed a change in their health or someone they care for within a few months of plasma-derived medicine treatment, with 77% expressing gratitude to donors. The survey also revealed high confidence in plasma-derived medicines' safety and efficacy.
Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.
CBL-514 selectively induces apoptosis of fat cells, reducing subcutaneous and visceral fat volume by 10.45% and 22.21% respectively in phase 2 clinical trials. The drug was well-tolerated with mostly mild-to-moderate injection-site reactions.
Researchers found trevogrumab significantly reduced lean mass loss by 50% when used with semaglutide. Participants who received trevogrumab experienced a mean increase in lean mass of +0.4%, while those who received placebo experienced a mean decrease of -2.4%.
The ACHIEVE-4 study shows orforglipron pills offer superior weight loss and blood sugar control compared to insulin glargine, but with a higher gastrointestinal adverse event rate. Non-inferiority for cardiovascular safety and superiority for weight reduction were demonstrated.
The phase 2b study evaluates the safety and efficacy of eloralintide in combination with tirzepatide, resulting in substantial weight loss and improvements in blood sugar control. The study demonstrated substantial weight loss and reduction in glycated haemoglobin (HbA1c) across different dosing combinations.
Real-world study data from Germany, Austria and Luxembourg show that GLP-1 receptor agonist drugs improve weight (37% reduction ≥ 5%), blood sugar control (glycaemic improvement) and systolic blood pressure in children and adolescents with type 2 diabetes. These benefits remained significant after adjustment for other factors.
Women are more likely to experience weight loss and improved blood sugar control with GLP-1 RAs, but face higher rates of side effects and unequal access to treatment worldwide. Extensive research is needed to address these disparities and optimize treatment for women in various domains.
A systematic review of 43,000 women with diabetes exposed to GLP-1 RAs found no significant associations with preterm birth, stillbirth, or neonatal death, but evidence gaps remain for early pregnancy loss and postpartum use. Further research is needed to address these gaps and provide clearer evidence for women with diabetes
Petrelintide, an amylin-based obesity drug, shows significant weight loss of over 10% in a phase 2 trial, with fewer gastrointestinal side effects compared to GLP-1 drugs. The study also reveals improvements in key cardiovascular risk factors, such as blood pressure and lipid parameters.
Retatrutide demonstrates substantial weight loss and improved blood sugar control in adults with overweight and type 2 diabetes, with 47% of participants losing at least 20% of their starting weight. The treatment also improves cardiometabolic risk factors and reduces inflammation.
A phase Ib/II trial evaluated the triple combination of famitinib, dalpiciclib, and fulvestrant in HR+/HER2− breast cancer, meeting initial efficacy targets with a confirmed objective response rate of 51.9%. However, the regimen showed no superiority over standard first-line treatments and was terminated early due to safety concerns.
A Danish study suggests that GLP-1 drugs could protect heart health in millions of people with overweight. The research found that individuals with a BMI of 25-26.9 and high remnant cholesterol and/or low-grade inflammation have a similar risk of coronary heart disease as those eligible for GLP-1 RAs for weight loss.
A new drug, Kamuvudine K-9, has been shown to preserve nerve fibers and halt neurological damage in a mouse model of multiple sclerosis. The drug, derived from HIV drugs, has been found to be more effective than existing treatments in restoring function and reducing inflammation.
The new guidelines, developed by leading experts, focus on improving sepsis care by strengthening systems for diagnosis, treatment, prevention, and quality improvement. Emerging technologies, such as next-generation diagnostics and artificial intelligence, are also being explored to enhance sepsis care.
Young people with HIV who receive injections every eight weeks manage their condition better than those taking daily tablets, according to a study published in The Lancet. The injections suppressed the virus more effectively, with only 1% of participants experiencing viral rebound, compared to 6% on daily tablets.
UVA researchers will use AI-assisted tools to develop a digital model showing how hormone differences impact medication effectiveness in women. The model will be tested on bacterial vaginosis and metabolic dysfunction-associated steatotic liver disease, with the goal of creating personalized predictions and more targeted drug therapies.
Researchers are evaluating the health and economic consequences of subpar buprenorphine dosing among Medicaid-covered pregnant women to improve maternal and infant outcomes. Data suggest that up to 90% of pregnant women require higher doses of buprenorphine.
A study published in JAMA found that intravenous loberamisal increased the proportion of patients with acute ischemic stroke achieving full functional outcomes at 90 days. The treatment resulted in a higher proportion of patients regaining full functional abilities compared to placebo.
University of California, Davis researchers successfully synthesized new compounds with reduced hallucinogenic and cardiotoxic effects, identifying one compound with antipsychotic-like effects. By systematically deconstructing LSD, they uncovered the importance of the phenethylamine-like traits in producing hallucinogenic effects.
Scientists at MUSC Hollings Cancer Center discovered a protein called lysyl oxidase that helps triple-negative breast cancer cells survive. Blocking LOX creates a weakness, which can be exploited with a second drug to block tumor growth without chemotherapy.
A $3.3 million NIH grant will support a five-year study on opioid treatment during breastfeeding, aiming to improve drug safety for lactating mothers. The researchers will develop a cell-based assay and use physiologically based pharmacokinetic models to predict drug levels in mothers and infants.
The updated guideline recommends routine obesity screening, comprehensive lifestyle intervention, and individualized use of medications and endoscopic and surgical procedures. Obesity should be treated as a chronic disease requiring longitudinal, flexible care pathways.
Researchers have identified several existing TGA-approved medicines that could slow brain damage in children with Sanfilippo syndrome, a devastating childhood dementia. The study used lab-grown brain cells and AI to rapidly test approved drugs and pinpoint those that improve brain cell health.
A recent study by the Ethiopian Public Health Institute and the JAMA Network has identified emerging drug and diagnostic resistance variants as contributing factors to Ethiopia's malaria resurgence. The study highlights the need for continued monitoring and adaptation of treatment strategies to combat the growing malaria epidemic.
A comparative study of 11,681 US cancer clinical trials reveals that industry-sponsored trials focus on single-agent drug therapies, while federally sponsored trials evaluate nontreatment interventions and rare cancer therapies. The study highlights the differences in trial design and objectives between industry and federal funding.
Researchers discovered that psilocybin reorganizes brain patterns, revealing hidden order, with stronger reorganisation linked to positive psychological changes. The study's findings have implications for developing therapies to improve clarity and psychological flexibility.
Surzen Biotherapeutics aims to develop effective pain relief without severe side effects by targeting opioid receptor pathways differently. The company plans to use peptides to block dimerization, reducing tolerance and improving efficacy.
A new study found a 17-fold increase in intravenous iron use among Australian women aged 18-44, with over 82 million dollars spent on the treatment. The study highlights the growing awareness of iron deficiency's impact on women's health, but also raises questions about access to equitable treatment.
The RadiCaL study, the first randomized trial of a radiopharmaceutical in kidney cancer, found that adding radium-223 to the standard of care does not improve skeletal event-free survival. Patients who received the combination treatment lived a median of 28.3 months, compared with 19.7 months for those who received cabozantinib alone.
Researchers at Virginia Tech developed a wearable microneedle patch called the iNal patch that can detect fentanyl in the body and automatically release naloxone to reverse an opioid overdose. The patch uses porous silica nanoparticles loaded with naloxone, which is released when fentanyl levels are detected.
Researchers highlight unanticipated benefits of GLP-1 medications, including reduced inflammation and lower risk of certain cardiovascular and musculoskeletal conditions. However, questions remain about lean body mass and nutritional health following weight loss associated with these medications.
A retrospective cohort study found that patients treated with aripiprazole had a lower risk of hyponatremia than those on olanzapine. This association could inform clinical decision-making for high-risk patients, despite residual confounding considerations.
By focusing on the specific regions of antibodies responsible for recognizing disease targets, the AI model improved binding affinity prediction and required fewer computational resources. This approach is similar to human-language AI models, where smaller domain-specific models trained on high-quality data can outperform larger ones.
Researchers at UH College of Pharmacy are developing breakthroughs to combat sepsis, a leading cause of hospital deaths, and diseases such as Alzheimer's and sickle cell disease. A dual-action nanomedicine has shown a 100% survival rate in preclinical trials for sepsis treatment.
Researchers developed a method to predict how different types of breast cancer will respond to treatment using lab-grown mini tumors. The organoids mimicked a tumor's response to treatment and identified candidate combination therapies for cancers that don't respond to standard treatment.
A new study found that patients from wealthier European countries tend to start biologic treatments earlier but stop or switch treatment earlier, experiencing lower disease activity. The study highlights the importance of ensuring timely and equitable access to effective treatment for patients with PsA and axSpA.
SourceElsevier·JournalAnnals of the Rheumatic Diseases·TypeData/statistical analysis·DateAug 11, 2026